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Background: The fungal roquefortine/meleagrin gene cluster is a source of diverse bioactive molecules.
Results: Novel metabolites of the roquefortine/meleagrin biosynthetic pathway were discovered, and synthetase genes were
assigned to biosynthetic reactions.
Conclusion: Distinctive unspecificity of modifying enzymes leads to excessive branching in the pathway, resulting in various
intermediates and products.
Significance: Metabolites from the roquefortine/meleagrin gene cluster have potential antimicrobial and chemotherapeutic
application.
Metabolic profiling and structural elucidation of novel sec-
ondary metabolites obtained from derived deletion strains of
the filamentous fungus Penicillium chrysogenum were used to
reassign various previously ascribed synthetase genes of the
roquefortine/meleagrin pathway to their corresponding prod-
ucts. Next to the structural characterization of roquefortine F and
neoxaline,which are for the first time reported forP. chrysogenum,
we identified the novel metabolite roquefortine L, including its
degradation products, harboring remarkable chemical struc-
tures. Their biosynthesis is discussed, questioning the exclusive
role of glandicoline A as key intermediate in the pathway. The
results reveal that further enzymes of this pathway are rather
unspecific and catalyze more than one reaction, leading to
excessive branching in the pathway with meleagrin and neoxa-
line as end products of two branches.
The filamentous fungus Penicillium chrysogenum has been
commercially exploited for many decades due to its high pro-
duction of -lactam antibiotics such as penicillin G (1). Next to
penicillins, secondary metabolites such as roquefortines and
glandicolines were isolated from liquid cultures of P. chrysoge-
num, which showpharmaceutically interesting properties, such
as neurotoxic (2), antimicrobial (3, 4), and antitumor (5) activ-
ities. They are structurally closely related and arise from the
roquefortine/meleagrin pathway, which contains a dimodular
nonribosomal peptide synthetase flanked by six associated
genes (6, 7). Startingwith histidyltryptophanyldiketopiperazine
(HTD),5 synthesized by the core synthetase enzyme RoqA
using tryptophan and histidine as substrates, RoqD catalyzes
the reversed prenylation of HTD at the C-3 of its indolemoiety,
utilizing dimethylallyl diphosphate to form roquefortine D. At
the same time, RoqR, a cytochrome P450 oxidoreductase, oxi-
dizesHTDat its histidinylmoiety to dehydrohistidyltryptopha-
nyldiketo piperazine (DHTD). Both simultaneous reactions of
HTD lead to a branch of the roquefortine/meleagrin pathway,
one to DHTD via the oxidation by RoqR and further to roque-
fortine C by dimethylallyl addition of RoqD, and the other via
an alteration of the enzymatic order. There, dimethylallyl addi-
tion is first performedbyRoqD to yield roquefortineD,whereas
further oxidation is carried out by RoqR, yielding roquefortine
C (see Fig. 1). Although several labeling, silencing, and deletion
experiments have been conducted, there is still ambiguity about
the subsequent biosynthetic reactions and the genes involved.
For instance, roquefortine C is supposed to be converted into
glandicoline A and further to glandicoline B with RoqM and
RoqO each catalyzing one reaction (6, 7). However, their assign-
ment to a particular reaction is still unclear. In addition, neoxaline
was proposed as final product of the pathway, originating from a
hydrogenation ofmeleagrin (8), yet no gene could be found in the
roq gene cluster performing that reaction.
Here, we describe the quantification, structural identifica-
tion, and biosynthesis of five previously unidentified metabo-
lites, obtained from highly sensitive comparative metabolite
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profiling of host and deletion strains. Roquefortine F and
neoxaline, next to the three structurally novel compounds, which
we named roquefortine L, M, and N, were found to be derived
from the roquefortine/meleagrin pathway. These results dem-
onstrate a further branching of this secondarymetabolite path-
way yielding a variety of intermediates with complex structures
and a diverse range of activities.
EXPERIMENTAL PROCEDURES
Host Strains, Media, Grown Conditions, and Plasmid Con-
struction—P. chrysogenum strain DS54555, which lacks both
the penicillin cluster genes and the ku70 gene, was used as a
host strain for deletion analysis and was kindly supplied by
DSM Anti-infective (Delft, The Netherlands). All the strains
were grown on YGG medium for protoplast formation and
transformation. For analysis, cells were grown on secondary
metabolite productionmedium (7) (glucose, 5.0 g/liter; lactose,
75 g/liter; urea, 4.0 g/liter; Na2SO4, 4.0 g/liter; CH3COONH4,
5.0 g/liter; K2HPO4, 2.12 g/liter; KH2PO4, 5.1 g/liter) for sec-
ondary metabolite production using a shaking incubator at 200
rpm for 168 h at 25 °C.
Metabolite Profiling—All strains used for gene assignments
were grown in quintuplicate to increase statistical power,
according to the procedure described above. Sample prepara-
tion was carried out as described previously (7). Metabolomic
profiling was performed on an Agilent 1200 capillary pump
(Agilent, Santa Clara, CA) coupled to a Surveyor photodiode
array detector (Thermo Scientific) and an LTQ-FT-ICR-Ultra
mass spectrometer (Thermo Scientific) equipped with an elec-
trospray interface as described earlier (7).
Metabolite Identification—The identity of compound 10was
confirmed by comparing retention time andMS fragmentation
spectra to its commercially available standard, purchased from
Bio-Connect (Huissen, TheNetherlands). Compounds 6, 9, 11,
and 12 were identified using NMR after extraction from liquid
cultures. 6 was extracted from the roqN deletion strain culture
filtrate, which wasmade alkaline with 25% ammonium hydrox-
ide (pH 10) and extracted with dichloromethane. The alkaline
dichloromethane layer was evaporated to dryness, redissolved
inwater containing 50% acetonitrile, vortexed, centrifuged, and
transferred to an autosampler vial for fraction collection via
preparative reversedphaseLConanAtlantisT3column(10100
mm, 5 m) (Waters, Milford, MA). Compound 9 was extracted
following the isolation procedure above except using culture fil-
trate of the roqOdeletion strain,whereas11 and12were obtained
from the same culture filtrate after lyophilization and extraction
using methanol. The methanol layer was evaporated to dryness,
redissolved in water, vortexed, centrifuged, and subjected to
repeated semipreparative chromatography as described above.
Elemental composition of compounds 6, 9, 11, and 12was deter-
mined using high-resolutionMS. NMR spectra were recorded on
aBrukerAvance III 700MHzor600MHzspectrometerwith sam-
ple temperatures ranging from 260 to 300 K, depending on the
particular requirements for each sample. By choosing an optimal
acquisition temperature, severe line broadening could be avoided,
which was observed for various signals due to conformational
averaging. For acquisition, samples were dissolved in equal
amounts of dimethyl sulfoxide (DMSO) and CDCl3.
Chemical Stability of Compound 6—An aqueous solution of
compound 6 was adjusted to pH 2.5 by the addition of formic
acid. Metabolite profiling was carried out as described above.
Products, formed by a degradation of 6, were compared with
extracted standards using HPLC-MS/MS.
RESULTS
Metabolite Profiling of Host and Deletion Strains Leads to
Five New Metabolites of the Roquefortine/Meleagrin Pathway—
In a previous study, we described the identification of various
abundant metabolites and resolved the major enzymatic steps
belonging to the roquefortine/meleagrin pathway (7). To iden-
tify secondarymetabolites originating from the roq gene cluster
(Fig. 1A), culture supernatants of the host strain and individu-
ally roq gene deletion strains were subjected to comparative
metabolite profiling using HPLC-UV-MS (Fig. 2). As host
strain, P. chrysogenum DS54555, which is derived from the
industrial DS17690 strain lacking the ku70 gene and multiple
penicillin biosynthetic genes clusters, was used. Here, we
describe the identification and quantification of several less
abundant metabolites, roquefortine L (6), roquefortine F (9),
neoxaline (10), roquefortine M (11), and roquefortine N (12)
(Fig. 1B), that have not been previously considered or structur-
ally characterized, filling missing biosynthetic reaction steps in
the roquefortine/meleagrin pathway.
Structure Elucidation and Quantification of 6, 11, and 12—
Compound 6 is a novel complex metabolite composed of a
roquefortine scaffold and a rare nitrone moiety, thus named
roquefortine L. The mass-to-charge ratio of its corresponding
ion was observed at 404.1706 using HPLC-FT-ICR-MS, repre-
senting the protonated molecule [MH] with formula
C22H22N5O3 (calc. 404.1717) eluting at 16.8 min. The same ion
was previously tentatively identified as glandicoline A (13) (Fig.
1B) as elemental composition and parts of the structure indi-
cated consistency with this compound (7). However, its 1H and
13CNMRdata showedhigh similarity to the diketopiperazine4,
indicating a roquefortine-like core structure. Furthermore, its
1H NMR spectrum revealed two protons at C-8 representing a
single bond between C-8 and C-9, which is different from the
double bond described for 13 (Table 1). Additionally, C-2 (C
146) in the 13C HMBC spectrum indicated a double bond
between N-1 and C-2, which was supported by the chemical
shift of N-1 (N  280) in the 15N HMBC spectrum. As com-
pound 13 was reported from various Penicillium species such
as Penicillium albocoremium (8), Penicillium glandicola (9),
and P. chrysogenum (10) and proposed as a precursor of 7, host
and roq deletion strain chromatograms of P. chrysogenumwere
further analyzed for the presence of 13. The chromatogram of
the ion with m/z 404.1706, representing the protonated mole-
cule [MH] with formula C22H22N5O3 of both compound 6
and compound 13, was extracted in a 5-ppm mass accuracy
window. However, no ion possibly corresponding to 13 could
be found, whereas 6 was observed at high concentration in the
liquid media (Fig. 3). The absence of 13 in host and various
P. chrysogenum strains lead to the conclusions that 13 is not
produced by P. chrysogenum DS54555.
Compounds 11 and 12 are novel compounds based on a
roquefortine-like scaffold, thus named roquefortine M and
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roquefortine N. High-resolution electrospray ionization mass
spectrometry of 11 (m/z 422.1814 [MH], calc. 422.1824) and
12 (m/z440.1918 [MH], calc. 440.1928) established themolec-
ular formula C22H23N5O4 and C22H25N5O5. Their chemical
structure was determined using 13C HMBC, 15N HMBC, and
1HNMR (Table 2) showing similar signals as observed for com-
pound 6,which indicates a similar chemical scaffold. However,
the significant upfield shift of N-1 (from N 280 in 6 to N
185 in 11) in the 15NHMBC spectra together with the chemical
shift of C-2 (C  146 in 6, C  172 in 11) in the 13C NMR
spectra of compound 11 shows that 11 contains a single bond
between N-1 and C-2, with C-2 being a carbonylic carbon. In
addition, a comparison between the 15N HMBC spectrum of
compounds 11 and 12 revealed that the amide bond between
N-14 and C-13 in 11was hydrolyzed in 12 (N 32.0), yielding
a primary amine and a carboxyl group. Both compounds com-
monly occur, together with compound 6, in liquid cultures of
P. chrysogenum host and roqT, roqN, and roqO deletion strains
(Fig. 3). Their absence in the remaining deletion strain samples
concludes the involvement of roqA, roqR, roqD, and roqM in
their biosynthesis.
Structure Elucidation andQuantification of 9 and 10—Com-
pound 9 with molecular formula C23H25N5O3, established by
high-resolution electrospray ionization mass spectrometry
(m/z 420.2015 [MH], calc. 420.2030), was identified as
roquefortine F, a metabolite solely reported from a deep ocean
sediment-derived Penicillium species (11), using 1H and 13C
NMR (Table 1). Its 1H NMR spectrum is very similar to the
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FIGURE 1. Roquefortine/meleagrin biosynthetic gene cluster and proposed corresponding pathway. A, organization of the roquefortine/meleagrin
biosynthetic gene cluster. B, proposed roquefortine/meleagrin pathway. Numbers between brackets are compound identifiers used throughout this study.
Enzymatic catalyzed reactions are indicatedby solid arrows, whereas chemical reactions are indicatedbydashed arrows. Structures shown inbrackets couldnot
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FIGURE 2. HPLC-MS elution profiles of novel metabolites of the meleagrin/neoxaline pathway. The HPLC-MS total ion chromatogram (black) and nor-
malized extracted ion chromatograms (colored) of the novel secondarymetabolites roquefortine N (12, 15.1 min), roquefortineM (11, 16.5 min), roquefortine
L (6, 16.8 min), neoxaline (10, 17.8 min), and roquefortine F (9, 22.8 min) from the meleagrin/neoxaline pathway are shown.
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spectrum of 3 (7), except for a double bond between C-12 and
C-15. Furthermore, the presence of C-26 (C 63.6) in the 13C
NMR spectrum, next to a sharp OCH3 peak (H  4.01) and a
missing proton on N-1 in the 1H NMR spectrum, fully agrees
with a methoxylated N-1 in compound 9. This was supported
by the absence of correlations with a carbon or proton in the
HMBC spectrum. The concentration of 9, particularly high in
the host strain, was found to be reduced to approximately one-
third in the deletion strains of roqT and roqO and absent in the
remaining deletion strains (Fig. 3). These data suggest that roqO
and roqT are the only two genes not involved in the biosynthesis
of 9. Compound 10 with molecular formula C23H25N5O4 (m/z
436.1967 [MH], calc. 436.1979) was identified as neoxaline,
a metabolite previously isolated from Aspergillus japonicas
Fg-551 (12) and Penicillium tulipae (13), by comparing reten-
tion time and MS/MS fragments with its commercially avail-
able standard. Although the concentration of 10 in host and
roqT deletion strain is almost comparable, a 97% decrease was
FIGURE3. -Foldchangeof theconcentrationof secondarymetabolites fromtheroquefortine/meleagrinpathway indeletionstrainsascomparedwith
the host strain. Numbers in the table represent the internal standard corrected concentrations of secondary metabolites in supernatants of deletion strains
obtained from HPLC-UV-MS as compared with their concentration in the supernatant of the host strain P. chrysogenum DS54555. Cell coloring, representing
the -fold change,wasperformedona logarithmic scale.Red cells indicate a concentration increase,whereasgreen cells represent adecrease.White cells indicate
a complete absence of the metabolite in the deletion sample. Novel metabolites of the roquefortine/meleagrin pathway are shown with bold numbers.
TABLE 1
Chemical shifts of 1H, 13C, and 15N NMR of roquefortine L (6) and 1H
and 13C NMR of roquefortine F (9) ( in ppm)
roquefortine L (6) roquefortine F (9) 
     
 
 
  
 290 K 280 K 290 K   280K 280K 
 δH  δC δN   δH  δC 
1-NO -  280     
2  147.6   2 5.78 84.9 
3  58.2   3  60.5 
3a  137.9   3a  130.5 
4 7.49 124.3   4 7.30 124.5 
5 7.44 129.0   5 7.09 124.4 
6 7.52 128.6   6 7.27 128.8 
7 7.56 114.9   7 7.06 116.0 
7a  148.5   7a  150.9 
8 2.24, 2.95 24.5   8 2.40 37.7 
9 5.06 63.6   9 3.96 57.4 
10  164.9   10  164.5 
11-NH 10.77  136  11-NH 10.63  
12  122.2   12  * 
13  156.7   13  157.4 
14-N   127  14-N14   
15 6.57 112.2   15 6.44 109.1 
16  124.3   16  * 
17-N   *  18 7.75 136.9 
18 7.76 136.3   19-NH 12.82  
19-NH 12.42**  *  20 7.21 134.2 
20 7.49 132.1   21  40.5 
21  43.1   22 5.99 143.1 
22 5.79 141.5   23 5.09, 5.16 114.6 
23 5.06, 5.09 116.2   24 0.94 23.2 
24 0.86 22.4   25 1.07 22.4 
25 1.09 22.3   26 4.01 63.6 
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(*) Not observed.
(**) From spectrum at 280 K.
TABLE 2
Chemical shifts of 1H, 13C, and 15N NMR of roquefortine M (11) and
roquefortine N (12) ( in ppm)
roquefortine M (11) roquefortine N (12) 
      
    
 270K 300K 270K   280K 280K 300K 
 δH  δC δN   δH  δC δN 
1-NOH 10.56  185***   10.64**  * 
2  172.6     173.1  
3  65.9     54.5  
3a  124.7     124.7  
4 7.20 125.1    7.18 125.0  
5 7.02 121.6    6.99 121.1  
6 7.27 128.2    7.22 127.6  
7 6.95 106.8    6.93 106.4  
7a  142.9     142.7  
8 2.32, 2.60 35.6    2.09, 2.58 35.0  
9 3.20 52.3    2.74 52.6  
10  165.1     *  
11-NH 10.44  137   10.08**  * 
12  121.0     *  
13  160.1     *  
14-NH 7.38  118  14-NH2 6.57**  30 
15 6.26 108.7    8.02 107.1  
16  125.3     127.7  
17-N   262     * 
18 7.65 136.4    8.00 133.4  
19-NH 12.87  169   *  196 
20 7.09 133.8    7.18 127.6  
21  41.9     41.7  
22 6.00 142.3    6.03 142.5  
23 4.98, 5.09 113.9    4.98, 5.09 113.4  
24 1.04 21.7    1.07 21.4  
25 0.96 21.3    0.98 21.2  
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(*) Not observed.
(**) Tentative assignment.
(***) From spectrum at 290 K.
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observed in the roqO deletion strain (Fig. 3). In all remaining
deletion strains, compound 10 could not be detected, leading to
the conclusion that all genes in the roq gene cluster, except
roqT, are required for the synthesis of 10.
Chemical Degradation of Compound 6 Leads to Various Prod-
ucts—Nitrones, such as compound 6, are not infinitely stable
and degrade already at room temperature in aqueous solution
as well as under acidic conditions by incorporation of water
(14–16). To determine the resulting degradation products, an
aqueous solution of 6 was acidified, and the resulting sample
was measured using HPLC-UV-MS (Fig. 4). Next to a 50%
decrease of 6, two highly abundant ions were observed in the
treated sample corresponding to 11 and 12. Additionally, a third
unidentified compound was found eluting at 17.33 min with a
mass-to-charge ratio of 422.1823, representing the protonated
molecule with the formula C22H24N5O4. These results demon-
strate that 11, 12, and an unidentified third compound are pro-
duced by degradation of the rather unstable compound 6.
DISCUSSION
Here, we present new insight into the complex biosynthesis
of secondary metabolites from the roquefortine/meleagrin
pathway. Five novel metabolites were found to originate from
the roq gene cluster, obtained from comparative metabolites
profiling of the host strain and various deletion strains in com-
binationwithNMR- andMS-based structure elucidation. As all
five metabolites are produced in a late stage of the pathway, no
changes were observed for the biosynthesis of upstreammetab-
olites 1–4, which starts with RoqA taking L-histidine and
L-tryptophan as substrates and producing compound 1. Based
on the highly significant accumulation of 4 in the roqM deletion
strain and the absence of all downstream metabolites 6–12
(Fig. 3), it can be concluded that roqM, encoding a flavin-de-
pendent MAK 1-monooxygenase-like protein, is involved in
the conversion of 4 into 6, a novel compound containing an
unusual nitronemoiety. Nitrones arewidely knowndue to their
free radical-trapping properties and their potential application
as therapeutics in age-related diseases (17) such as cancer (18)
and ischemic stroke (19). As the chemical scaffold of compound
6 is closely related to the roquefortine group, it was named
roquefortine L. Flavin-containing monooxygenases are com-
monly known to consecutively oxidize drugs and xenobiotics
containing a soft nucleophile, such as nitrogen or sulfur (20). In
the case of secondary amines, flavin-containing monooxyge-
nases consecutively oxidize the nitrogen, leading to the produc-
tion of hydroxylamines and nitrones (14–16). A similar mech-
anism for the synthesis of the nitrone-containing compound 6
is very likely, startingwith the oxidation of the secondary amine
in the indole part of 4, yielding the hydroxylated intermediate 5
(Fig. 5). Further oxidation on the same nitrogen produces an
unstable N,N-dihydroxylated species, which is followed by the
loss of water, eventually producing compound 6. However,
nitrones are not indefinitely stable and easily degrade at room
temperature in aqueous solutions (14–16). Under acidic con-
ditions, compound 6 decomposes by a consecutive incorpora-
13 14 15 16 17 18 19 20
Time (min)
12
6
11
FIGURE 4. Chemical degradation of compound 6 leads to various prod-
ucts. The total ion chromatograms of pure (black) and degraded (blue) com-
pound 6, after the addition of formic acid, measured on HPLC-MS are shown.
Acid-induced degradation leads to the formation of 11 and 12 next to an
unidentified compound eluting at 17.33 min with [MH]  422.1823 and
elemental composition C22H23N5O4.
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FIGURE 6.Degradation of compound 6 yielding 11 and 12 by consecutive incorporation of water.
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tion of water leading, among others, to the production of com-
pounds 11 and 12 (Fig. 4 and 6). This decomposition was also
observed in NMR experiments after extended storage of a solu-
tion of 6 at room temperature. These results suggest that the
presence of 11 and 12 in liquid cultures of P. chrysogenum can
be attributed to a chemical degradation of 6. Compound 6,with
the formula C22H21N5O3, is represented by an ion with a mass-
to-charge ratio of 404.1706 and eluting at 16.8 min. The exact
same ion was previously tentatively identified as compound 13
(7) as its elemental composition, and parts of the structure indi-
cated consistency with this compound. However, further struc-
ture elucidation using variousNMRexperiments confirmed the
structure of 6 instead. This was surprising as compound 13, a
proposed key intermediate in the biosynthesis of downstream
metabolites such as 7, 8, and 10, was previously tentatively
identified in different Penicillium cultures (8, 10). By using a
comparable instrumental setupwith a similar chromatographic
separation method, host and deletion strains of DS54555 were
screened for production of 13. Nevertheless, neither 13 nor
corresponding degradation products could be detected,
whereas 6 was found at high concentrations, leading to the
conclusion that 13 is not produced by P. chrysogenum. This is
remarkable as 13 was expected as single precursor of 7, modi-
fied by RoqO (6). In addition, a deletion of roqO resulted in an
up to 98% decrease of 7, whereas the levels of upstreammetab-
olites remained nearly unchanged, indicating that RoqO is
indeed involved in the synthesis of7. Due to the general absence
of 13 in the P. chrysogenum-derived samples, compound 7 has
to originate from a different biosynthetic route than the previ-
ously reported oxidation of 13 on its indole nitrogen (6–8).
RoqO, encoding a P450 monooxygenase, closely resembles
FtmG (64% identity, 79% similarity at the amino acid level), a
cytochromeP450monooxygenase catalyzing the hydroxylation
of fumitremorgin C to dihydroxy-fumitremorgin C (21), com-
pounds that are structurally similar to the roquefortine deriva-
tives. A possible deduced biosynthesis of 7 involves the
hydroxylation of 6 on C-9 by RoqO, comparable with the oxi-
dation of fumitremorgin C by FtmG. Subsequent cleavage of
the bond between C-9 and N-14 followed by the development
of a bond between C-2 and N-11 is postulated to ultimately
yield 7, similar to the mechanism previously proposed for 13
from 4 (22). These results, together with the general absence of
13 in P. chrysogenum, lead to the conclusion that 7 and 8 are
produced via a different biosynthesis in P. chrysogenum than in
other Penicillium strains such as P. tulipae (8), for which a ten-
tatively identified 13 was reported as intermediate.
The deletion of roqN resulted in an accumulation of 7 in the
liquid medium, whereas metabolites 8, 9, and 10 were absent
(Fig. 3). RoqN, a methyltransferase, was previously recognized
to catalyze the addition of a methyl group on the hydroxylated
nitrogen of 7, producing 8 (6, 7). As 9 contains a methylated
hydroxylamine group in the same position as 8, the hydroxyla-
mine containing compound 5, which differs only in a methyl
group, is proposed as its direct precursor with RoqN catalyzing
the methyl addition to yield 9. These results reveal a further
branching of the roquefortine/meleagrin pathway with com-
pounds 6 and 9 being products of 5. In addition, they support
the presence of 5,whichwas proposed based on its involvement
in the biosynthesis of 6.
Compound 10 was previously proposed as direct product of
8 by enzymatic hydrogenation (8). However, BLAST analysis
did not reveal an enzyme in the roquefortine/meleagrin path-
way that is able to perform that reaction (6, 7). Moreover, a 53
times higher concentration of8 as comparedwith10 in the host
strain, but the absence of 8 in the roqO deletion strain with 10
still being present, leads to the conclusion that 8 is not a pre-
cursor of 10 (Fig. 3). In contrast, due to the high concentration
of 9 in the roqO strain and its roquefortine-like structure
(roquefortine scaffold with a methoxy group on N-1), com-
pound 9 is proposed as direct precursor of 10 with RoqO cata-
lyzing this reaction, similar to the synthesis of 7 from 6. These
results suggest that RoqO is involved in the reactions from 6
into 7 and from 9 into 10 by oxidizing and subsequently con-
verting a roquefortine scaffold into a glandicoline-like structure
(Fig. 1B).
In conclusion, these results extend the additional branch of
compound 9 leading to the final product 10. Unspecificity,
already observed for RoqR and RoqD (7), could now also be
observed for RoqO and RoqN, leading to a complex degree of
branching in the pathway and a wide palette of compounds.
Several of the new compounds identified in the current study
were found to be equippedwith interesting biological activities.
Roquefortine F, previously reported from a deep ocean sedi-
ment-derived fungus Penicillium sp., shows moderate cytotox-
icity against various tumor cell lines (11). Neoxaline, which was
first isolated from A. japonicas Fg-551, stimulates the central
nervous system in mice (12) and inhibits cell proliferation (23).
Furthermore, it was found to induce cell cycle arrest at the
G2/M phase in Jurkat cells (inhibition of tubulin polymeriza-
tion) (23). Here, the novel metabolites roquefortine L, roque-
fortineM, and roquefortineN are added to the palette of poten-
tial cytotoxic compounds, which demonstrates the potential of
engineered industrial P. chrysogenum strains to produce novel
bioactive compounds with unusual chemical scaffolds.
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